NOVARTIS BANGLADESH FD SAYS SOUTH ASIAN EMERGING GIANT IS A TOUGH MARKET TO CRACK
January 1st, 2014
BANGLADESH’S pharmaceuticals industry lacks a “level-playing field,” leaving multinationals to wade through a raft of regulatory restrictions which may not apply to locally-owned manufacturers, a top official of Novartis Bangladesh said.“This is a very challenging market. There are lots of restrictions on multinational companies,” Sazzad Rahim Chowdhury, finance director at the Swiss drug giant, told Manufacturing Chemist.“Any two molecules manufactured locally can’t be imported. We can’t produce here OTC [over-the-counter] drugs, like vitamins. ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.